The European Medicines Agency recently handed VIVUS (Nasdaq: VVUS) an official rejection for its obesity drug Qsymia, leading Arena (Nasdaq: ARNA) shareholders to wonder if this creates a major opportunity for the pharmaceutical company's competing drug, Belviq.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.